Filing summary
Entity and period: The supplied filing is Oculus Innovative Sciences, Inc.’s Form 10-Q for the quarter ended June 30, 2014 (its fiscal 2015 first quarter), not a Sonoma Pharmaceuticals filing. The financial statements are unaudited. Amounts below are in U.S. dollars.
Business context and financial results
Oculus develops and sells healthcare products based primarily on its Microcyn technology, including wound-care, dermatology and animal-health products, and operates a contract-testing laboratory. It reported sales in 33 countries.
- Revenue: $3.392 million, up 0.6% from $3.372 million. Product revenue was $2.795 million, licensing fees $375,000 and services $222,000.
- Profitability: Gross profit was $1.906 million, down from $2.200 million; gross margin was approximately 56%, versus 65%. Product gross margin fell to 58% from 68%, which management attributed in part to lower U.S. animal-health and dermatology sales. Operating loss widened to $1.514 million from $1.126 million.
- Net result: Net loss was $70,000 ($0.01 per share), compared with $1.712 million ($0.26 per share) a year earlier. A $1.478 million noncash gain from revaluing warrant derivative liabilities substantially reduced the reported loss; it did not reflect improved operating performance.
- Cash flow: Operating cash use was $1.346 million, versus $1.057 million. Investing cash use was $8,000. Financing provided $869,000, mainly from ATM share sales, partly offset by $83,000 of debt payments. Cash declined $493,000 during the quarter to $4.987 million.
- Balance sheet and liquidity: Working capital was $2.981 million, versus $1.970 million at March 31, 2014. Total debt was approximately $64,000; current liabilities totaled $5.687 million. The company held a $10.150 million long-term investment in Ruthigen, carried at cost.
Material changes and management commentary
- U.S. product and licensing revenue by geography declined 22% to $1.028 million; Mexico increased 3% to $1.470 million; Europe and the rest of the world increased 65% to $672,000. Total product and licensing revenue across those regions increased 1%.
- Revenue from Innovacyn, a related-party distributor, fell to $528,000 from $741,000. Innovacyn notified Oculus that it plans to transition to another supplier over the following 12 months. Oculus is seeking replacement channels; management cautioned that revenue may be adversely affected.
- Research and development expense declined 13% to $439,000, partly because the prior-year period included Ruthigen costs. SG&A rose 6% to $2.981 million; management expects it to increase as the company expands its direct sales force. Management expected R&D expense to decrease over the next few quarters.
- The company sold 300,000 shares through an at-the-market program during the quarter, receiving $952,000 net. The program permits sales of up to $9.159 million, subject to a 3% commission. An additional 15,120 shares generated $43,000 net through August 6, 2014.
Outlook, risks and unusual items
Management expected cash and cash equivalents to fund working capital, sales and marketing, and R&D efforts through at least July 1, 2015. It also expected continued losses and said further capital may be needed for product development and market expansion. No additional financing was committed; unavailable or unfavorable financing could require reduced spending, including R&D. U.S. pivotal clinical trials to pursue drug commercialization were to be delayed until a funding partner or additional capital was obtained.
- Revenue was concentrated: one customer represented 43% and another 16% of quarterly revenue. The filing also reports significant customer concentration in receivables.
- At June 30, 2014, derivative warrant liabilities were $1.697 million, down from $3.175 million, based on Level 3 valuation inputs. The resulting fair-value gain was a major, noncash contributor to the improved net loss.
- Oculus disclosed potential executive severance of $1.130 million under certain termination circumstances. It said ordinary-course legal matters were currently insignificant, while noting litigation could have a material adverse effect.
- The company had FDA 510(k) clearances for certain device uses but lacked U.S. approval to market Microcyn as a drug or with antimicrobial or wound-healing indications. Regulatory approval, product efficacy, competition, distribution execution and capital access were identified as risks.
- Management reported effective disclosure controls at the reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing identity: the document names Oculus Innovative Sciences, Inc., whereas the request metadata names Sonoma Pharmaceuticals, Inc.
- Assess the underlying operating trend separately from the $1.478 million noncash derivative revaluation gain, including the wider operating loss and lower gross margins.
- Monitor cash use, the stated runway, ATM issuance capacity and actual subsequent fundraising; additional financing was not secured.
- Track Innovacyn’s supplier transition and the replacement of its distribution revenue, alongside customer and receivables concentration.
- Review the assumptions supporting the $10.150 million Ruthigen investment carried at cost, and the Level 3 warrant-liability valuation.